KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to -$117.8 million.

  • Sarepta Therapeutics' Cash from Financing Activities fell 95621.87% to -$117.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.1 million, marking a year-over-year decrease of 20306.98%. This contributed to the annual value of $124.8 million for FY2024, which is 15.84% down from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Cash from Financing Activities is -$117.8 million, which was down 95621.87% from -$23.8 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Cash from Financing Activities registered a high of $549.2 million during Q4 2021, and its lowest value of -$117.8 million during Q3 2025.
  • Over the past 5 years, Sarepta Therapeutics' median Cash from Financing Activities value was $10.7 million (recorded in 2022), while the average stood at $48.1 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 356704.51% in 2022, then plummeted by 95621.87% in 2025.
  • Sarepta Therapeutics' Cash from Financing Activities (Quarter) stood at $549.2 million in 2021, then plummeted by 98.04% to $10.7 million in 2022, then plummeted by 81.92% to $1.9 million in 2023, then soared by 2421.41% to $49.0 million in 2024, then plummeted by 340.43% to -$117.8 million in 2025.
  • Its Cash from Financing Activities was -$117.8 million in Q3 2025, compared to -$23.8 million in Q2 2025 and $12.5 million in Q1 2025.